Startups

Aerska
Aerska develops RNA medicines for neurological diseases. Its antibody-oligonucleotide conjugate platform uses brain shuttle technology to deliver RNA interference therapeutics across the blood-brain barrier and silence disease-associated genes. Its initial research focuses on genetically driven forms of Alzheimer’s and Parkinson’s disease. The company is headquartered in Dublin, with research operations in London and a Boston site announced in June 2026; its platform remains in development.
Founded 2025



